A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503444-13-00

Acronym

64007957MMY3006

Enrollment

291

Registered

2024-07-02

Start date

2023-03-29

Completion date

Unknown

Last updated

2025-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory multiple myeloma

Brief summary

progression free survival (PFS)

Interventions

DRUGDexamethason 4 mg JENAPHARM®

DRUGteclistamab

DRUGPomalidomide

DRUGFortecortin® 2 mg Tabletten

DRUGVELCADE 3.5 mg powder for solution for injection

DRUGImnovid 4 mg hard capsules

DRUGDexamethason 8 mg GALEN® Tabletten

DRUGDexamethasone Tablets BP 2.0mg

DRUGImnovid 3 mg hard capsules

DRUGImnovid 1 mg hard capsules

DRUGPrivigen 100 mg/ml solution for infusion

DRUGKyprolis 60 mg powder for solution for infusion

DRUGImnovid 2 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
progression free survival (PFS)	—

Countries

Austria, Belgium, Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026